Link Cell Therapies launched with a $60 million Series A to develop next‑generation CAR‑T therapeutics against solid tumors and announced strategic backing tied to Johnson & Johnson. The startup aims to commercialize modular CAR‑T platforms that improve trafficking and persistence in solid tumor microenvironments, an area where cell therapies have struggled historically. The financing will fund translational work, early clinical development and manufacturing scale‑up. Company executives framed the round as a vote of confidence in cell therapy approaches that address solid‑tumor challenges through engineering of both effector cells and tumor‑microenvironment targeting strategies. Clarification: CAR‑T refers to chimeric antigen receptor T cells genetically engineered to target tumor antigens.